BioSpace News Archive

This study will provide a scientific rationale for the remodeling response and clinical improvements identified in the feasibility study

– Preliminary Results Showed 41% (9 of 22 Patients) Objective Response Rate, Including One Confirmed Complete Response – – Treatment was Generally Well-Tolerated with Treatment-Emergent Adverse Events Mostly Grade 1 or 2 – – Based on Preliminary Results, the Expansion Cohorts for DCC-3014 in TGCT Patients Opened at the Recommended Phase 2 Dose of 30 mg Twice Weekly –

Interim data from Phase 1 dose expansion cohort of mRNA-4157 in combination with pembrolizumab shared at The Society for Immunotherapy of Cancer’s Annual Meeting 2020 Data support expansion of Head and Neck Squamous Cell Carcinoma (HNSCC) cancer patient cohort Praveen Aanur, MBBS joins Moderna as Vice President, Therapeutic Area Head for Oncology Development

Potential to revolutionize nitric oxide therapy by eliminating need for cumbersome cylinders creating im proved economics and safety in hospital setting Will be subject to a 180-day review period by the FDA Launch expected in 2Q 2021, pending approval

Aleafia Health Inc. (TSX: AH, OTC: ALEAF) (“ Aleafia Health” or the “ Company ”) is pleased to report its financial results for the three and nine months ended September 30, 2020 (“ Q3 2020 ”). “We expect to have our strongest quarter to date in Q4 2020 as we progress towards significant sequential growth in medical, adult-use, wholesale and international cannabis sales. The strategic path we’ve executed upon, from building out facilities, to receiv

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that management will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020 , at 8:00 am E.T.

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the Jefferies 2020 Virtual London Healthcare Conference on Wednesday, November 18, 2020, at 2:40 PM GMT/9:40 AM ET.

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020 at 4:40 p.m. Eastern Time

Receptor Life Sciences (Receptor) today announced the appointment of Gregory T. Mayes, J.D. to its Board of Directors

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the Jefferies Virtual London Healthcare Conference